Channel Therapeutics

Executive Summary

Channel Therapeutics is a private biopharmaceutical company headquartered in San Diego, CA, focused on developing innovative, non-addictive small molecule therapies for chronic neuropathic pain and acute/chronic eye pain. Founded in 2018, the company leverages proprietary ion channel modulation to address significant unmet needs in pain management, aiming to provide safer alternatives to opioids and existing treatments. While specific pipeline details are not publicly disclosed, Channel Therapeutics is positioned to advance drug candidates targeting voltage-gated sodium and calcium channels, which are validated targets for pain relief. The company's early-stage status and lack of disclosed financing history suggest it is likely operating in the preclinical to early clinical development phase, with potential for near-term milestones such as IND filings or entry into Phase I trials. Given the high prevalence of chronic pain and the ongoing opioid crisis, Channel Therapeutics' approach has notable strategic value, though execution risk remains elevated due to the early stage and private nature.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Chronic Neuropathic Pain Candidate60% success
• Q2 2026Series A Financing Round70% success
• Q4 2026Preclinical Proof-of-Concept Data Presentation for Ocular Pain Program80% success